8-K: Cellectar Biosciences Announces Positive Clinical Trial Results and Q1 2024 Financials

Cellectar Biosciences reported positive topline data from its CLOVER WaM pivotal study and provided a corporate update along with its first quarter 2024 financial results.

Summary

• Cellectar Biosciences announced its financial results for the first quarter of 2024, along with a corporate update.
• The company's CLOVER WaM pivotal study for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) met its primary endpoint with a major response rate of 61%.
• The overall response rate in the CLOVER WaM study was 75.6%, and the company plans to announce data for all evaluable patients in June 2024.
• A Phase I study of iopofosine in combination with External Beam Radiotherapy in recurrent head and neck cancer showed a 64% complete remission rate and a 73% overall response rate in highly refractory patients.
• The company reported a complete central nervous system clearance in a relapsed/refractory WM patient, further validating iopofosine I 131's potential.
• The first patient was enrolled in a Phase 1b clinical study of iopofosine I 131 in pediatric high-grade gliomas (pHGG), supported by a $2 million grant.
• Preclinical data for CLR 121225, an alpha-emitting phospholipid radiotherapeutic conjugate, showed promise in pancreatic cancer models.
• Strategic partnerships were formed with Florida Cancer Specialists and American Oncology Network (AON) to advance WM treatment.
• As of March 31, 2024, Cellectar had $40.0 million in cash and cash equivalents, compared to $9.6 million at the end of 2023.
• Net cash used in operating activities for the quarter was approximately $13 million.
• The company believes its cash balance is sufficient to fund operations into the fourth quarter of 2024.
• Research and development expenses were approximately $7.4 million for the quarter, compared to $6.7 million in the same period of 2023.
• General and administrative expenses increased to $4.6 million, compared to $2.1 million in the first quarter of 2023.
• The net loss for the quarter was $21.6 million, or $0.74 per share, compared to a net loss of $8.6 million, or $0.76 per share, in the same period of 2023.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results and a strong cash position, but the significant net loss and increased expenses temper the overall sentiment. The company is making good progress but needs to manage its finances carefully.

Positives

• The CLOVER WaM study met its primary endpoint with a strong major response rate.
• The company has a strong cash position of $40 million.
• The company is progressing its clinical pipeline with multiple studies underway.
• Strategic partnerships with oncology networks are in place to advance treatment.
• The company has received a $2 million grant from the National Institute of Health's National Cancer Institute.
• The company is expanding its pipeline to include targeted alpha therapies.

Negatives

• The company experienced a significant net loss of $21.6 million for the quarter.
• General and administrative expenses have increased significantly.
• The company's net loss per share was $0.74, compared to $0.76 in the same period last year, despite the increased loss.

Risks

• The company faces risks related to raising additional capital.
• There are uncertainties related to disruptions at the sole source supplier of iopofosine.
• The company faces risks related to attracting and retaining partners for its technologies.
• The company faces risks related to the FDA review process and other government regulations.
• The company faces competition from other pharmaceutical companies.
• The company faces risks related to product pricing and third-party reimbursement.

Future Outlook

The company plans to announce data from the CLOVER WaM study in June 2024 and submit an NDA in the second half of 2024. They also expect to announce data from the phase 1b pediatric high-grade glioma study in the second half of 2024 and initiate a phase 1 study for CLR 121225 no later than first quarter 2025.

Management Comments

• We plan to announce data from our CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstroms macroglobulinemia in June and are on track to submit our NDA in the second half of 2024, said James Caruso, president, and CEO of Cellectar.
• We remain pleased with patient enrollment in the phase 1b pediatric high-grade glioma study and expect to announce data in the second half of 2024.

Industry Context

This announcement is significant in the context of the biopharmaceutical industry, particularly for companies focused on targeted cancer therapies. The positive results from the CLOVER WaM study and the progress in other clinical trials position Cellectar as a notable player in the development of novel cancer treatments. The partnerships with oncology networks also indicate a strategic approach to commercialization.

Comparison to Industry Standards

• The 61% major response rate in the CLOVER WaM study is competitive with other targeted therapies for relapsed/refractory Waldenstrom's macroglobulinemia.
• The 75.6% overall response rate is also a strong result, indicating a high level of efficacy for iopofosine I 131.
• The 64% complete remission rate in the head and neck cancer study is notable, especially in highly refractory patients, and compares favorably to standard treatments.
• The company's cash position of $40 million is relatively strong for a clinical-stage biopharmaceutical company, providing runway for further development.
• The increase in G&A expenses is typical for a company preparing for potential commercialization, but the magnitude of the increase is significant and should be monitored.

Stakeholder Impact

• Shareholders will be encouraged by the positive clinical trial results and the company's strong cash position.
• Employees may be positively impacted by the company's progress and potential for growth.
• Patients with Waldenstrom's macroglobulinemia and other cancers may benefit from the development of new treatment options.
• The company's partnerships with oncology networks may lead to increased access to treatment for patients.

Next Steps

• The company will announce data for all evaluable patients in the CLOVER WaM study in June 2024.
• The company plans to submit an NDA for iopofosine I 131 in the second half of 2024.
• The company expects to announce data from the phase 1b pediatric high-grade glioma study in the second half of 2024.
• The company plans to initiate a phase 1 study for CLR 121225 in either triple negative breast or pancreatic cancer no later than first quarter 2025.

Key Dates

Keywords

Cellectar Biosciences, Iopofosine I 131, Waldenstroms macroglobulinemia, CLOVER WaM, Cancer treatment, Radiotherapy, Clinical trial, Phase 1b, Pediatric high-grade gliomas, Phospholipid Drug Conjugate, CLR 121225, Alpha therapy, Financial results, NDA submission